AACP
VYGR icon

Advantage Alpha Capital Partners’s Voyager Therapeutics VYGR Stock Holding History

Advantage Alpha Capital Partners’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-110,681
Closed -$875K – 194
2024
Q2 		$875K Sell
110,681
-11,630
-10% -$97.5K 0.19% 89
2024
Q1 		$1.14M Sell
122,311
-54,560
-31% -$461K 0.21% 93
2023
Q4 		$1.49M Buy
+176,871
New +$1.28M 0.28% 88

Other funds holding VYGR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Advantage Alpha Capital Partners's VYGR Position: Q3 2024 in Review

Advantage Alpha Capital Partners sold out of Voyager Therapeutics (VYGR) in Q3 2024, closing a stake of 110,681 shares — an estimated $875K sold.

Advantage Alpha Capital Partners first reported a position in VYGR in Q4 2023 and held it in 3 quarters. The position peaked at $1.49M in Q4 2023. 128 funds tracked by Wall St. Rank hold VYGR as of Q3 2024.

  • Advantage Alpha Capital Partners reported no remaining Voyager Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Advantage Alpha Capital Partners sold 110,681 Voyager Therapeutics shares in Q3 2024, an estimated $875K.
  • Advantage Alpha Capital Partners first reported a position in Voyager Therapeutics in Q4 2023 and held it in 3 quarters.
  • Advantage Alpha Capital Partners's Voyager Therapeutics position peaked at $1.49M in Q4 2023.
  • 128 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2024.

Based on Advantage Alpha Capital Partners's 13F filing for Q3 2024, filed 13 Nov 2024.